Parallel Bio Announces $4.3M Seed Funding

December 20, 2022Client News

Gunderson Dettmer represented client Parallel Bio, a biotechnology company, in its $4.3 million seed round led by Refactor Capital. Parallel Bio created a human immune system in a petri dish intended for testing new drugs without using humans or animals to change the way diseases are cured. The company will use the new capital to continue its drug research, development, and discovery.

In the announcement of the transaction, co-founder and CEO of Parallel Bio Robert DiFazio said, “Nearly 95 percent of drugs that make it to clinical trials fail, even when they work on animals first. With this funding, we’ve been able to turn that failure into an opportunity to cure disease at a pace never seen before by starting with human systems first.”

The Gunderson Dettmer team was led by Cody Peterson and includes Vanessa Smith, Bess Benhamou, Marna Pattaropong and Rebecca Harris. 

Parallel Bio 
Refactor Capital